MiR‐146a‐5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor‐alpha inhibitor adalimumab
暂无分享,去创建一个
A. Procopio | A. Offidani | F. Olivieri | M. R. Rippo | F. Marcheselli | A. Campanati | E. Molinelli | F. Prattichizzo | R. Recchioni | K. Giuliodori | E. Mensà | V. Consales
[1] Jingwen Deng,et al. Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers , 2017, Experimental dermatology.
[2] Luca Tiano,et al. Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells , 2016, Oncotarget.
[3] R. Testa,et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications , 2015, Oncotarget.
[4] E. Edson-Heredia,et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. , 2014, The Journal of investigative dermatology.
[5] F. Abad‐Santos,et al. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases , 2013, The Pharmacogenomics Journal.
[6] C. Franceschi,et al. MiR-146a as marker of senescence-associated pro-inflammatory status in cells involved in vascular remodelling , 2012, AGE.
[7] A. Esquela-Kerscher,et al. The complexities of microRNA regulation: mirandering around the rules. , 2010, The international journal of biochemistry & cell biology.
[8] B. Kaczkowski,et al. MicroRNAs and potential target interactions in psoriasis. , 2010, Journal of dermatological science.